key: cord-0883260-2j6caq91
authors: Luong, Huy Xuan; Thanh, Tung Truong; Tran, Tuan Hiep
title: Antimicrobial peptides – Advances in development of therapeutic applications
date: 2020-09-12
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118407
sha: c1dc6eecb1cfb98a9c2683744596678fa82a6116
doc_id: 883260
cord_uid: 2j6caq91

The severe infection is becoming a significant health problem which threaten the lives of patients and the safety and economy of society. In the way of finding new strategy, antimicrobial peptides (AMPs) - an important part of host defense family, emerged with tremendous potential. Up to date, huge numbers of AMPs has been investigated from both natural and synthetic sources showing not only the ability to kill microbial pathogens but also propose other benefits such as wound healing, anti-tumor, immune modulation. In this review, we describe the involvements of AMPs in biological systems and discuss the opportunity in developing AMPs for clinical applications. In the detail, their properties in antibacterial activity is followed by their application in some infection diseases and cancer. The key discussions are the approaches to improve biological activities of AMPs either by modifying chemical structure or incorporating into delivery systems. The new applications and perspectives for the future of AMPs would open the new era of their development.

The antibiotic drug resistance and shortage of new antibacterial drugs putted medical care at risk of severe infections. In the quest of new antimicrobial strategies, antimicrobial peptides (AMPs) have showed a great potential. AMPs have been widely investigated in both mechanisms of action and new therapeutic applications [1, 2] . Most of clinical study until now, are focusing on its antimicrobial properties and the posible for topical administration. Nonetheless, many recent reports suggested that AMPs also show promising characteristics for wound recovery, anti-cancer, as well as new cosmetic ingredients [3] [4] [5] .

Though AMPs are potential in drug development they still have several undesirable properties for clinical application. Natural peptides are usually unstable in gastrointestinal track and other body fluids, poor absorption and distribution while fast metabolic degradation and excretion, which result in low bioavailability [6, 7] . Their flexible structures also may possibly induce interactions with unintended components, which could result in undesirable side-effects. Furthermore, according to the DRAMP Database, there are approximately 67% To overcome these challenges, recently both chemical and bioengineering strategies have been proposed to develop potent, selective and metabolically stable peptide preparations with cheaper price and less tendency to trigger undesired side-effects. These innovative techiques together with new findings in biological roles make antimicrobial peptides become an emerging category for clinical applications [13] [14] [15] . In this review, the development of AMPs as therapeutic agents is summarized in which their properties and applications are discussed.

Moreover, the delivery of them and the chemical modification are also introduced to pave the way of translating them to the clinical practice. 

According to the WHO, lower respiratory infection in 2016 became the fourth worldwide leading cause of death and the first in low-income country. Together with pneumonia and bronchitis, infections in lower respiratory tract also markedly contribute to chronic inflammatory lung disorders such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and asthma [70] . However, antibiotic treatment -the most effective medical intervention is facing a growing problem of microbial resistance.

In our respiratory system, AMPs were produced by neutrophils airway epithelial cells to prevent the continuous exposure to various inhaled pathogens. The roles of AMPs are shown through the broad-spectrum antimicrobial activity including multidrug resistant (MDR) bacteria and those present in biofilms as well as the indirect activities in shaping the lung immune response and improving wound healing by promoting angiogenesis and inducing airway epithelial cell repair. In fact, the serum level of human cathelicidin antimicrobial peptide LL-37 in bacterial lung infected patients was reported to be significantly higher than that of healthy volunteers [71] .

In the opposite side, the lack of AMPs could seriously weaken the protection ability. In mice, the deficiency of cathelin-related antimicrobial peptides (CRAMP) leads to the consequence of more sensitive to bacterial pneumonia infection. Some in vivo studies also 

Microbial keratitis has several challenges for treatment, which in fact is the most common cause of corneal blindness in the world. However, the efficacy of conventional antibiotics is rapidly reducing due to the involvement of microbial resistance. Keratitis is frequently poly-microbial with bacterial infections in combination with fungal, parasitic or both, which licensed drugs for those two are few and far between. Thus, AMPs have the potential ability to answers to almost all the challenges listed. Furthermore, AMPs are also proven to induce corneal wound healing in eyes [78, 79] . containing LyeTxI-b reccently has showed effective in the treatment of keratitis with resistant bacterial while no signs of ocular toxicity found. In more details, LyeTxI-b could eliminate bacteria and reduce both inflammatory cellular activity and biofilm viability in the eyes [80] . In development of artificial corneal skirt, the corneas with AMP-immobilized Titan (via a crosslinker -polydopamine) compared to those with unprotected Titan implants, showed lower incidence and lesser extent of bacterial infection [81] .

Furthermore, the combination of a certain AMP with other antibiotics, ophthalmic corticosteroids or AMPs also holds promise in dealing with wide range of eyes problems to enhance the effectiveness of treatment while reducing the dose required. Such a proper combinations can help limit the toxicity of both antibiotics and corticosteroids, which can cause ocular surface damage and more scarring itself [82] .

Helicobacter pylori (or H. pylori) causes the most morbidity and prevalence of chronic infection in the human stomach [83] . This Gram-negative bacterium specifically hijacks immune responses including evading the host defense shield and selectively compromising AMPs production to allow colonization [84] [85] [86] [87] . Moreover, H. pylori can also promote (hepatic) J o u r n a l P r e -p r o o f malignancy both inside and outside of the gastrointestinal (GI) tract, even if it translocates across the intestinal barrier or not [88] .

In fact, the resistance problem of H. pylori to antibiotics such as clarithromycin, amoxicillin or metronidazole is well-documented, especially in developing world including Africa [89, 90] . Nonetheless, the drug-resistance emergence, the cost as well as the side effects H. pylori properties in vitro [91] . However, to be success in vivo, the essential requirements of AMPs applications includes having long duration staying in stomach while being relatively stable and remaining their antimicrobial potency in gastric environment. An example is a antimicrobial peptide TP4 displayed potent antimicrobial activity against H. pylori strains both in vitro and in vivo while high doses did not cause any detected toxicity in mice or rabbits [92] . In addition, Zhang and colleagues suggested that manganin was also a potent antimcirobial peptides against H. pylori and it became more effective when administrated in the nanoparticles form [93] .

Human intestines are frequently exposed to the threats of various pathogenic microorganisms. Thus, a long with enzymes and friendly bacteria, AMPs are commonly J o u r n a l P r e -p r o o f produced in intestinal mucosa as an important part of intestinal barriers. Therefore, the balance between intestinal microbes and host AMPs keeps the intestinal tract healthy [94] .

Recently, some studies suggest that disruption of the gut microbiota by regular antibiotic treatment can weaken mucosal barrier and lead to invade of pathogens and intestinal inflammation [95] . Moreover, antibiotic administered in early life may cause long-term consequences on immune response as well as metabolic homeostasis and gut microbiota composition [96, 97] . Those problems together with the widespread problem of bacterial resistance lead to an urgent need for more effective and safe antimicrobial agents.

Several efforts for antimicrobial peptide development are in progress, for instance, coprisin -an natural peptide derived from Korean dung beetle were demonstrated to prevent inflammation as well as mucosal damage in Clostridium difficile infection [98] . Besides, cathelicidin-WA was introduced to inhibit inflammation while enhance intestinal barrier function in weaned piglets and mice, which open a potential therapy for the treatment of diarrhea and other intestinal diseases [16] .

It should be noted that one of the big challenges for oral application is the low stability of AMPs in gastric acid and various protease in gastrointestinal system. However, it could be solved by many strategies, such as chemical modifications including non-natural amino acids incorporation, cyclic peptides or pseudo-peptides [99] ; nano delivery systems [100, 101] or AMP-antibiotic combinations [102] . Furthermore, AMPs can also be delivered to the site of intestinal infection by engineering the probiotic bacteria [103] .

J o u r n a l P r e -p r o o f

Bone infections (also called osteomyelitis) can lead to many consequences such as protracted infected lesions, necrotic bone formation, implant loosening and surgical failure, which usually prolong and require and enormous treatment efforts [104] . As over 1.5 million total hip and knee replacement (TKR) procedures performed annually in the United States, bone infection became the most severe and devastating risk related to orthopedic implants [105, 106] .

Furthemore, the annual treatment cost in the USfor prosthetic joint infection is estimated to exceed $1.62 billion by 2020 [107] . Regarding to all orthopedic subspecialties, the incidences of infection range from 0.1% to 30% with a cost of $17 000-$150 000 per patient as reported by the 2018 International Consensus Meeting on Musculoskeletal Infection [108] .

In fact, local or systemic antibiotics are popular for removal surgery and the treatment of bone-related infections [109] [110] [111] . Nonetheless, it not only results in increased emergence of antibiotic resistance [111] but also induces osteolysis, for instance, gentamicin inhibits osteoblast viability or vancomycin prevents osteoblast proliferation at certain concentrations [112] . Thus, the discovery of new antimicrobial agents to cure infection while improves or at least be harmless to osseointegration should be clinically significant. Therefore, antimicrobial peptides are potential for joint and bone infection treatment, which is commonly complicated because of the resistance to the classical antibiotics and the formation of bacteria biofilm.

Bormann et al. reported high antimicrobial potency of some AMPs against bacteria both incorporated in a biofilm or internalized into cells with no harm to human osteoblasts [113] . value than the two traditional antibiotics vancomycin and gentamincin but was found to be significantly more effective than those antibiotics when separately loaded into the calcium phosphate cement. Moreover, AMP-loaded poly(methyl methacrylate)-based bone cement can also prevent microbial adhesion as well as subsequent formation of biofilm on their surface as compared to vancomycin and control loaded cement [60] .

Regarding toxicity, Pavel and collegues suggested no signs of local or systemic side effects in laboratory rats has found since their infected femurs were treated with antimicrobial peptide [59] . Although these studies demonstrated the multiple benefits of AMPs for bone and implant-related infections, still there are several issues needed to examine, including the permeability of AMPs into the surrounding bone tissues; the stability and efficacy of AMPs in bone environment as well as carrier materials; the long-term effect on osteoblast proliferation.

Antimicrobial peptides produced by gingival epithelial cells contribute the first line of defense system against wide range of oral pathogens. The importance of AMPs were reported in many reports such as type 1 diabetes patients having single-nucleotide polymorphisms (SNPs) in genes encoding HBD-1 are associated with high rates of Candida albicans carriage [115] .

Moreover, patients with deficient cathelicidin peptide (LL-37) and human neutrophil peptides generally experience oral infections and periodontitis (severe periodontal diseases) [116] . The concentrations of human neutrophil peptides 1 to 3 in children saliva without caries are much higher than those with caries [115] . These interesting findings suggest that normal amount of antimicrobial peptide concentrations can control the growth of oral bacteria and fungi, thus preventing caries and other types of infections.

Dental caries (also known as tooth decay or cavities) is one of the most common global chronic diseases [117] . Several therapies have been developed for preventing tooth decay, however, all current anti-caries approaches have their disadvantages. For instance, sodium fluoride toothpaste -the most popular one is nonselective intervention [118] . Silver diamine fluoride (SDF) option is simple, non-invasive with inexpensive equipment and low risk of spreading infection. However, SDF treatment is not a complete therapy for caries risk and its drawbacks include unpleasant metallic taste, mucosal and gingival irritation as well as the black staining of the tooth surfaces [119] . [120, 121] . Besides, pHresponsive antimicrobial peptides is another great approach could be considered [122, 123] .

Oral mucositis and candidiasis are common complications in patients receiving chemotherapy and radiation treatment. Lesions of oral infection are not only painful, significantly affect nutritional support as well as oral hygiene but also increase risk of local and systemic infection [124] . In fact, there is no drug approved by FDA for preventing or treating radiation and chemotherapy-related oral mucositis. A topical antimicrobial peptide called Iseganan originally showed promising in reducing mucositis symptoms but failed to show efficacy at phase III clinical study [125, 126] .

Oral candiasis frequently caused by Candida albicans fungus can be a serious problem for those wearing dentures [127] or with a weakened immune system, for examples children, elderly people and patients taking steroids, radiation treatment, having AIDS or having type 1 diabetes [128] [129] [130] . Since oral antifungal drugs have many possible undesirable side effects including mouth irritation, diarrhea, nausea or even more serious such as irregular heart rhythm, live failure, etc., topical application of AMPs holds great opportunities as novel oral diseases treatment. Until now, the mouth rinse product containing antimicrobial peptide PAC113 from Pacgen Biopharmaceuticals just passed phase II clinical trial for the treatment of oral candidiasis in HIV patients [126, 131] . [134] . Polybia-MP1 was also well studied for the interaction with PS on the membrane and PS was found to impact on the lytic properties of MP1 [135] . In another study, it is suggested that MP1 could form the pore on the cell membrane by the support of combination of PS and phosphatidylethanolamine (PE) lipids [136] which have a mutual relationship and together alter the membrane of cancer cells [137] .

The investigation of AMP and cell membrane are supported effectively by studying the interaction between AMP and artificial lipid bilayers vesicles with variety of lipid compositions.

Those studies suggested a lot of insights the real scenarios to develop AMPs as anticancer agents [138] [139] [140] .

On the other way of approach, AMPs are able to internalize the cells and interact with intracellular compartments such as mitochondria and induce cell apoptosis [141] . Peptide m2386 from a lactic acid bacterium Lactobacillus casei ATCC334, induced the expression of Fas and TRAILR1 death receptors on the cell surface of treated SW480 cells and also kill cancer cells via the programmed cell death pathway [142] . The apoptosis was also enhanced in cancer cells after exposure to Parasporin, a non-insecticidal crystalline protein of Bacillus thuringiensis [143] ,

Hexokinase II -derived cell-penetrating peptide [144] and more.

LTX-315 -a cationic antimicrobial peptide with oncolytic properties is even found to not only kill the cancer cells but also reprogram the tumor microenvironment with a decrease of immunosuppressive Tregs and myeloid-derived suppressor cells and increase frequency of polyfunctional T helper type 1/type 1 cytotoxic T cells which is very promising for anti-cancer immunotherapy [145] . Immunotherapy for cancer treatment is getting closer to the clinical practice in which AMPs are also gaining their role as an important component of evolutionary biology [146, 147] J o u r n a l P r e -p r o o f

The feature of an AMPs is demonstrated in Fig. 2 . The most common conformation of AMPs is alpha helix structure [18, 56] Beta sheet is characterized by the presence of an antiparallel beta-sheet, mostly stabilized by disulfide bonds. Some β-sheet antimicrobial peptides: Tachyplesins, Protegrins, Bactenecin [9, 149, 150] . Linear/extended peptides lack classical secondary structures, generally due to their high content of proline and/or glycine [151] [152] [153] . In fact, natural AMPs can have more than one type of secondary structure, for example Human beta defensins (HBDs) contain a combination of alpha helices and β-sheet [12, 56, 57] .

As the most common reported mechanism of actions of AMPs is membrane-lysis, the peptide sequences need to be long enough to span or insert into the hydrophobic layer of the membrane. Moreover, the lengths of AMPs are also important to maintain the required conformation and generally longer chain is better for forming secondary structure. Nonetheless, long sequence also means there are a certain percentage of dominant residues and higher cost of J o u r n a l P r e -p r o o f production. In fact, some studies suggested that the derived short version of many natural AMPs can have more potent antimicrobial activity while showing lower hemolysis effect [154] [155] [156] [157] .

Positively charge is a common property of AMPs provided by cationic amino acids such as Lysine, Arginine or the amino group at N-terminus, which also is a component of the hydrophilicity part in AMPs [158, 159] . The net positive charge and the distribution of charged residues is important for the initial binding step as well as the selectivity with the negatively charged membrane of bacteria species [160] , thus, too high cationic density can cause the reversed effects: less potent antimicrobial activity but more hemolytic activity [161] . In fact, most of the natural AMPs have the net charge from +2 to +10 [9] and some studies suggested the optimal net charge should depend on the length of sequence [162] [163] [164] .

Hydrophobicity is crucial for the interaction with the hydrophobic layer in bacteria membrane. Therefore, too low may result in weak bacteria membrane interaction and less permeability effect, however, highly hydrophobicity can induce hemolysis -one of the most common side effect [165, 166] . Thus, the percentage of hydrophobic residues is normally in the range of 40-60%. Furthermore, the higher hydrophilicity of AMPs can help reduce the hemolytic activities, however it may prevent the hydrophobic interaction with bacteria membranes. In fact, the killing activity and safety of AMPs depends on the balance hydrophobicity-hydrophilicity, especially to Gram negative species with thick and more complicated membrane components than Gram positive species. The optimal ratio between the two properties (hydrophobicity and hydrophilicity) can maximize the antimicrobial benefit while minimize the adverse side effect on human red blood cells [161] .

There are several amino acids that have been extensively studied due to its striking impact on the structure or activity of antimicrobial peptides. Proline and Glycine provides more J o u r n a l P r e -p r o o f flexibility for the peptide structure, which can help induce the hemolytic activity [151, 163] .

Tryptophan (W) is demonstrated to facilitate the interaction with bacteria membrane when it was put in the interface between hydrophobic face and hydrophilic face of the amphipathic helices [151, 161, 167] . Cysteine -an amino acid contains sulfur in its side chain which is strongly reactive. It could easily be oxidized to form a dimer, therefore generating a disulfide bond between two cysteines. These disulfide bridges are strongly hydrophobic and important for the structures of many natural antimicrobial peptides [168, 169] . It also can improve the resistance towards proteolytic degradation [170] . 

Pseudo-peptides. Peptidomimetics generally mimic the structure, activity and selectivity of antimicrobial peptides while improves plasma half-life. The most popular pseudo-peptide forms in this category is peptoids and beta-peptide [197] [198] [199] [200] [201] (Fig. 5) . Another promising approach in peptidomimetics is merged structures of native peptides and pseudo-peptides which results in hybrid structures [202, 203] . 

The potential of AMP triggers a huge attention, biologically. However, the way to bring those AMPs from bench to bed still requires much more effort, firstly, how drugs are administered to patients. In general, AMPs like other peptides are undergone a couple of challenges including low permeability due to large molecular size, short residence time at the absorption site and quick degradation due to variety of enzymes or body fluids [204] . In the context of this section, we discuss about the obstacles by individual administration routes and respective solutions, up to date, to enhance the bioavailability of AMPs.

J o u r n a l P r e -p r o o f

Transdermal delivery. Developed since long time ago, transdermal benefits patients by the painless administration, ease of termination, also the sustained release, and avoidance of firstpass metabolism regarding the substance [205] . However, being as the first and most important barrier to protect body, human skin turns out to be the challenges for this administration route.

The outmost layer of the skin -stratum corneum consisting of non-living cells, corneocytes and multiple lipid bilayers restricts the diffusion of drugs. Following that, before being absorpt to blood circulation, the drugs need to overcome the difficulties in epidermis -the layer lacking blood vessels, as well [206] . The approaches to advance transdermal administration are divided into two categories: enhancing drug diffusion through the intact skin and physically disrupt and bypass the barrier [207] .

Oral delivery. Oral delivery offers patients the most convenient in usage, thus being the most widely used route. The development of delivery technology is able to facilitate the oral administration of AMPs, but it still needs to be improved to overcome challenges. Firstly, AMPs are the big molecules which restrains them being transported across the GI tract walls [204] .

Another practical barrier is the intestinal mucus, above the intestinal epithelial, containing the glycosylated proteins forming a steric shield to limit molecular diffusion or epithelium interaction of biologics [208] . Last but not least, the assemblage of bile salts, gastric acids and proteases at different stages even can degrade or structurally disturb biologics resulting in eliminating their function before the absorption [209] . To address those difficulties, the advantages of delivery technology are able to control over dissolution rate, residence time;

preserve molecules from chemical hazards; enhance the absorbance using absorption and permeation enhancers [205] . A couple of advanced systems is also developed such as nanoparticles, hydrogels, mucoadhesive matrixes [210] . On the other hand, medical device types like microneedles or intestinal patches offer biologics ability to bypass those challenges [211, 212] .

Inhalation delivery. The large surface area and widely distributed vascularization in the lungs offer a rapid systemic absorption for biologics via inhalation route. In order to reach to the lung, the formulations should be delivered deep into lung which required a crucial optimization of size, density, shape and other physical properties [213] . Following by that, the biologics will interact with pulmonary surfactant containing lipid and protein secreted by type II alveolar cells.

In addition, the presence of enzymes and mucus layer also can dampen out the biologics resulting in limited absorption [214] . A couple of strategies could be approached including mucopenetrative, mucoadhensive methods permeation enhancers, cell-penetrating peptides or improving particles properties [215] .

Subcutaneous delivery. Still maintaining a high bioavailability of substance but improving the acceptance and compliance of patients comparing to intravenous route, subcutaneous delivery is attracting the attention in biological delivery system development. The main challenge of this administration route is penetrating through extracellular matrix where physiological components like protein, antibody, immune cells may interact and aggregated active molecules. This way of drug administration is also limited by the injected volume [216] .

The development of polymeric particles advances the delivery by controlling release, physically separating the biologic from the subcutaneous microenvironment and improved dispersion using hyaluronidases. The other stimuli-responsive like glucose, pH or target systems also improve the diffusion and absorption of biologics [217] .

Generally, compared to systemic absorption, topical administration can minimize systematically adverse such as hemolytic or allergy while less prone to be degraded by enzymes.

In fact, most of AMPs in the clinical phase until now are prepared in topical applications, especially for oral and skin disease indications. This route of administration in many cases required the effective penetration of antimicrobial peptides into the skin. As AMPs mostly consist of long sequences which limits its large molecules to be absorbed, several strategies have been applied to improve the bioavailability, for examples antimicrobial hydrogels [218] , lipidbased nanocarriers [219] , poly(lactic-co-glycolic acid (PLGA) nanoparticles [220] or gold/silver nanoparticles conjugation [221] [222] [223] . In addition, the importance of delivery formulation can be shown in protecting AMPs from degradation or maintaining AMPs activity in such conditions as J o u r n a l P r e -p r o o f high salt concentration, low pH or dryness. Furthermore, not only the penetration ability but also the released kinetic from topical formulation to the surrounding area need to be assessed.

The medical devices are becoming a hall-mark in modern health care systems with varieties of types such as implantable devices, artificial heart valves, catheters [224] ( Table 1) .

Over the past century, the more popular of this artificial aid is, the more risk is increased. Most of those interacts with one or some opened wounds of human body that is threaten by infection during treatment. Staphylococcus aureus and Staphylococcus epidermidis are the most common causative microorganisms that were found in biomaterial-associated infections (BAI) [225] .

Those bacteria strains are able to develop biofilms on the surface of devices, and/or form tissue colonizations then possibly promote antimicrobial resistance to dampen the efficacy of antibiotic treatment [226] .

In the detail, bacteria tend to attach to the surface of medical devices then proliferate and create an extracellular matrix containing bacteria, bacterial exopolysaccharides, proteins, extracellular DNA, and host proteins [227] . This complex matrix restrains antibiotic drugs from interaction with bacteria and attenuate their activity to target pathogen. In another approach, bacteria invade surrounding tissue and form bacterial colonization which is known as small colony variants. Those small "outbreak" gives more troubles for antimicrobial compounds [228] .

Last but not least, along with the abuse of antimicrobials, many strains were found to resistant with one or several drugs. Interestingly, those bacteria are evolved frequently in the hospital environment where all of devices-based interventions are taken place [229] .

AMPs are expected to be candidates which can harmonize the implant area by interact with pathogen membranes inducing depolarization, destabilization, and/or disruption of the bacterial plasma membrane [230] . Furthermore, AMPs are also known to manipulate immune system which indirectly eradicate pathogens [231] or escalate wound healing [232] , angiogenesis process [233] . By using AMPs, the medical devices are expected to be protected via three different mechanisms [234] . Firstly, the surface of devices is modifying by charge, hydrophilicity using hydrophilic polymers or conjugate with polymer chains to form antifouling surfaces [234, 235] . In addition, AMPs are decorated on surfaces of medical devices to kill bacteria directly [235] . However, this approach may be limited because those AMPs can only inhibit replication of nearby bacteria and leave tissue-related issue unsolved. This drawback could be addressed by release systems by which the amount of antimicrobials is maintained and delivered to surrounding area at sufficient concentration to clean up any residual bacteria [236] . 

The antimicrobial peptide coating prevented both Gram-positive and Gramnegative bacterial adhesion by up to 99.9% and inhibited planktonic bacterial growth by up to 70%. In vivo, the peptide coating was tested in a mouse urinary catheter infection model. [238] Indolicidin

Prevent Candida albicans to form biofilms and impairs preformed mature biofilms [239] J o u r n a l P r e -p r o o f GL13K TiO 2 nanotubes Kill both F. nucleatum and P. gingivalis [240] FK- 16 Titanium surface Anti-adhesion and biofilm inhibition capabilities against both S. aureus and E. coli.

[241]

Polymer-Lipid Encapsulation MatriX

Effective in killing S. aureus and inhibiting biofilm [242] KYE28

Poly(ethyl acrylate-comethacrylic acid) microgels

Anti-inflammatory effects on human monocytes Potent antifouling properties [243]

AMPs as an essential part in maintaining a healthy skin hold promising potential in the development of new cosmetics. Some beneficial features of AMPs for cosmetic application include (i) clearance of skin pathogens through direct killing action and indirect immune modulatory, which is important for many skin problems, for examples, acne management due to inhibition of Propionibacterium acnes and inflammation control; (ii) wound healing promotion through multiple means covering cell proliferation, cell migration, angiogenesis, etc. [54, [244] [245] [246] ; (iii) anti-fibrogenic effect [247] [248] [249] , interestingly, some reports suggested that AMPs can suppress the excessive collagen synthesis following injury, thus indicated the excellent benefit for recovering wound without scarring [68] ; (iv) oxidative stress management [250, 251] .

Among those desirable characteristics, the most frequent is the improvement of tissue repair, followed by cell proliferation and migration, angiogenesis, anti-inflammation and other characteristics [4] . Recently, novel AMPs with multiples interested properties for cosmetic application can be mentioned as LL-37, temporin-1TL, Esculentin-1a, Psoriasin (S100a7),

LLKKK18, SR-0397 [4] . However, though possessing various advantages, application of AMPs J o u r n a l P r e -p r o o f in cosmetic industry is still rare, which mainly because of high production cost, low stability and poor understanding in mechanism of action.

Infection and cancer remain to be great challenges of human being. The race to an effective therapy is limited by the quick alternation of viruses, bacterium and cancer cells resulting in drug resistance. In this review, we summarized the knowledge about AMPs serving as the base for modification toward better efficacy in treatment.

The potential of AMPs in regulating immune system is expanding. Playing a key role in natural evolution, AMPs might be an important breakthrough in which AMPs are acting for direct therapies or indirect via immune-modulation. For example, a cathelicidin antimicrobial peptide D-CATH2-2 has been proven to modulate the immune systems and therefore partially support to the protection of newborn chickens later against E. coli infection challenge without any sign of harmful strong inflammatory response [252] . Thus, AMPs should be in call for a new paradigm of infection and cancer treatment and prevention, exploiting immune system.

Until now various chemical adjustment has been introduced to make AMPs shorter and promote its biological activities and stability, mostly. Besides, the mentioned delivery systems, on one hand, help to protect AMPs from hazardous environment, on the other hand, elevate the activity of them. In fact, though some synthetic peptides showed relatively stable and potent in several proposed conditions such as trypsin digestion or presence of salt and human serum [161, 253, 254] , it should be noted that there are still various proteases and other components (salt, DNA, pH, mucins, etc.) in body fluids that can effect on the stability and activity of peptides. Of note, many AMPs displayed promising in vitro, however unable to show activity in vivo [73, 255, J o u r n a l P r e -p r o o f Journal Pre-proof 256] . Therefore, the ability of AMPs that maintain its specificity as well as antimicrobial potential in real conditions critical point or the success of peptides.

Since conventional antibiotics are not only suffering from the threat of antimicrobial resistant but also being reported to cause long-lasting side effects such as multisystem toxicity syndromes by quinolone and fluoroquinolone antibiotics [96, 97, 257, 258] , AMPs were one of the most promising candidates for development of new alternative therapy. Some studies has reported the potential of antimicrobial peptides in combination with others antimicrobial peptides or conventional therapy [259] . Such a synergistic combination can help to increase the potency while reduce the therapeutic dose, side effects and the threats of drug resistance. In term of safety, many studies in vivo suggested almost no toxicity in laboratory mice at the low levels of AMPs.

This combination approach, could avoid the usage of high AMP levels that may cause side effects such as hemolysis, inflammation with uncontrolled immune cell recruitment or unintentionally binding.

However, many challenges have been preventing the clinical application of AMPs, such as poor "absorption, distribution, metabolism, excretion", bulky size, sensitive to the ambient conditions. Consequently, many AMPs were failed or denied approval in Phase III clinical trials, such as Pexiganan (MSI-78) for treatment of impetigo and diabetic foot ulcers, Iseganan (IB-367)

for mouth rinse to prevent infection in patient receiving chemotherapy, Locilex (22-amino acid magainin) for diabetic foot ulcers, Omiganan for catheter infaction. Several failures in the past have not discouraged efforts to put this product line into practical use. In contract, more and more AMPs are being tested with expanding list of potential applications for both human and animals [260] [261] [262] [263] . Therefore, it is very important to develop chemical modifications, J o u r n a l P r e -p r o o f Journal Pre-proof bioengineering strategies and combination approaches are strongly needed to improve the pharmaceutical properties of potential AMPs.

Overall, we believe with new advances in finding solutions that improve AMPs design as well as peptide production technologies, AMPs will provide a strong impact to the medical practices.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Antimicrobial host defence peptides: functions and clinical potential

The value of antimicrobial peptides in the age of resistance

Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds

Breaking the frontiers of cosmetology with antimicrobial peptides

Pro-necrotic Activity of Cationic Mastoparan Peptides in Human Glioblastoma Multiforme Cells Via Membranolytic Action

Strategic Approaches to Optimizing Peptide ADME Properties

Antimicrobial Peptides: Basics for Clinical Application

Truncated and constrained helical analogs of antimicrobial esculentin-2EM

DRAMP 2.0, an updated data repository of antimicrobial peptides

Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides

Computational resources and tools for antimicrobial peptides

DRAMP: a comprehensive data repository of antimicrobial peptides

Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice

Delivery systems for antimicrobial peptides

Multilayered coating on titanium for controlled release of antimicrobial peptides for the prevention of implant-associated infections

High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestine

Mode of action of membrane active antimicrobial peptides

Alpha-helical cationic antimicrobial peptides: relationships of structure and function

Effects of net charge and the number of positively charged residues on the biological activity of amphipathic α-helical cationic antimicrobial peptides

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

The expanding scope of antimicrobial peptide structures and their modes of action

Two Hits Are Better than One: Membrane-Active and DNA Binding-Related Double-Action Mechanism of NK-18

Mechanism of Action of the

Buforin II Kills Microorganisms by Penetrating the Cell Membrane and Inhibiting Cellular Functions

Antibacterial action of lactoferricin B like peptide against Escherichia coli: Reactive oxygen species-induced apoptosis-like death

Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design

Mechanisms of Action for Antimicrobial Peptides With Antibacterial and Antibiofilm Functions

Antimicrobial peptides: Application informed by evolution

Structural and Functional Assessment of mBjAMP1, an Antimicrobial Peptide from Branchiostoma japonicum, Revealed a Novel α-Hairpinin-like Scaffold with Membrane Permeable and DNA Binding Activity

Fast and potent bactericidal membrane lytic activity of PaDBS1R1, a novel cationic antimicrobial peptide

Antimicrobial activity and safety evaluation of peptides isolated from the hemoglobin of chickens

Antimicrobial peptides

Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies

Modulation of the TLR-Mediated Inflammatory Response by the Endogenous Human Host Defense Peptide LL-37

Peptides with dual mode of action: Killing bacteria and preventing endotoxin-induced sepsis

Defensins Protect Cells from Infection by Herpes Simplex Virus by Inhibiting Viral Adhesion and Entry

A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses

NP-1, a Rabbit α-Defensin, Prevents the Entry and Intercellular Spread of Herpes Simplex Virus Type 2

The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19

Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review

Antiviral activity of selected antimicrobial peptides against vaccinia virus

Peptide-based Antifungal Therapies against Emerging Infections

Global Phenotype Screening and Transcript Analysis Outlines the Inhibitory Mode(s) of Action of Two Amphibian-Derived, α-Helical, Cationic Peptides on Saccharomyces cerevisiae

The Cellular Target of Histatin 5 on Candida albicans Is the Energized Mitochondrion

Antimicrobial peptides with antiprotozoal activity: current state and future perspectives

Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges

Antichagasic effect of crotalicidin, a cathelicidin-like vipericidin, found in Crotalus durissus terrificus rattlesnake's venom gland

Yellow Biotechnology I: Insect Biotechnologie in Drug Discovery and Preclinical Research

Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii

Melittin peptide kills Trypanosoma cruzi parasites by inducing different cell death pathways

Biofilm infections, their resilience to therapy and innovative treatment strategies

A Broad-Spectrum Antibiofilm Peptide Enhances Antibiotic Action against Bacterial Biofilms

Human Host Defense Peptide LL-37 Prevents Bacterial Biofilm Formation

Antimicrobial peptides prevent bacterial biofilm formation on the surface of polymethylmethacrylate bone cement

Antimicrobial peptides and wound healing: biological and therapeutic considerations

Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance

APD3: the antimicrobial peptide database as a tool for research and education

CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides

Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice

Testing the efficacy of antimicrobial peptides in the topical treatment of induced osteomyelitis in rats

Antimicrobial Peptides for Topical Treatment of Osteomyelitis and Implant-Related Infections: Study in the Spongy Bone

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells

Lack of new antiinfective agents: Passing into the pre-antibiotic age?

Peptide-based treatment of sepsis

Peptides with dual mode of action: Killing bacteria and preventing endotoxin-induced sepsis

Frequent bacterial skin and soft tissue infections: diagnostic signs and treatment

Wound healing activity of the human antimicrobial peptide LL37

Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology

Antimicrobial Peptides in Cutaneous Wound Healing

Clinical Application of AMPs

Antimicrobial Peptides and Innate Lung Defenses: Role in Infectious and Noninfectious Lung Diseases and Therapeutic Applications

Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections. Cent

Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa

Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection

Modulating self-assembly behavior of a saltfree peptide amphiphile (PA) and zwitterionic surfactant mixed system

Modulating hierarchical self-assembly behavior of a peptide amphiphile/nonionic surfactant mixed system

Effects of Conventional Surfactants on the Activity of Designed Antimicrobial Peptide

Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia

The role of antimicrobial peptides at the ocular surface

Bioactive Antimicrobial Peptides as Therapeutics for Corneal Wounds and Infections

A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis

Effectiveness of antimicrobial peptide immobilization for preventing perioperative cornea implant-associated bacterial infection

Human antimicrobial peptides in ocular surface defense

Antimicrobial peptides in gastrointestinal inflammation

Differential Expression of Human Beta Defensin 2 and 3 in Gastric Mucosa of Helicobacter pylori-Infected Individuals

Cholesterol Enhances Helicobacter pylori Resistance to Antibiotics and LL-37

Immune evasion strategies used by Helicobacter pylori

Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance

How are the expression patterns of gut antimicrobial peptides modulated by human gastrointestinal diseases? A bridge between infectious, inflammatory, and malignant diseases

The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis

Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions

Review of antimicrobial peptides with anti-Helicobacter pylori activity

Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model

The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo

Susceptibility to infectious diseases based on antimicrobial peptide production

Antibiotic Treatment Alters the Colonic Mucus Layer and Predisposes the Host to Exacerbated Citrobacter rodentium-Induced Colitis

Antibiotics in early life alter the murine colonic microbiome and adiposity

Amoxicillin Alters Long-Term Immune Response Despite Transient Effects on Gut-Microbiota in Piglets

The Insect Peptide Coprisin Prevents Clostridium difficile-Mediated Acute Inflammation and Mucosal Damage through Selective Antimicrobial Activity

Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization

Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges

Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability

Synergistic Effects of Antimicrobial Peptides and Antibiotics against Clostridium difficile

pMPES: A Modular Peptide Expression System for the Delivery of Antimicrobial Peptides to the Site of Gastrointestinal Infections Using Probiotics

Prevalence of Total Hip and Knee Replacement in the United States

Evolving concepts in bone infection: redefining "biofilm

Economic Burden of Periprosthetic Joint Infection in the United States

International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions

Treatment algorithms for chronic osteomyelitis

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. The Lancet

Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults

Skull base osteomyelitis: Incidence of resistance, morbidity, and treatment strategy

A short artificial antimicrobial peptide shows potential to prevent or treat bone infections

The antimicrobial peptide KR-12 promotes the osteogenic differentiation of human bone marrow stem cells by stimulating BMP/SMAD signaling

Oral Antimicrobial Peptides and Biological Control of Caries

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study

Dental caries. The Lancet

Targeted Antimicrobial Peptides: A Novel Technology to Eradicate Harmful Streptococcus Mutans

UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent

Selective membrane disruption: mode of action of C16G2, a specifically targeted antimicrobial peptide

Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology

Lipid-packing perturbation of model membranes by pH-responsive antimicrobial peptides

The effect of pH on the lytic activity of a synthetic mastoparan-like peptide in anionic model membranes

Management of oral mucositis in patients who have cancer

Antimicrobial therapy to prevent or treat oral mucositis

Designing antimicrobial peptides: form follows function

Occurrence rate of oral Candida albicans in denture wearer patients

Single-Nucleotide Polymorphisms (SNPs) in Human β-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type I Diabetics and Nondiabetic Controls

Innate immunity to Candida albicans

Virulence factors of Candida albicans

Antimicrobial Peptides Under Clinical Trials

Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects

Membrane targeting cationic antimicrobial peptides

Phosphoinositide-mediated oligomerization of a defensin induces cell lysis

Phosphatidylserine lipids and membrane order precisely regulate the activity of Polybia-MP1 peptide

PE and PS lipids synergistically enhance membrane poration by a peptide with anticancer properties

Distinct localization of lipid rafts and externalized phosphatidylserine at the surface of apoptotic cells

New insight into the mechanism of action of wasp mastoparan peptides: lytic activity and clustering observed with giant vesicles

The insertion of Polybia-MP1 peptide into phospholipid monolayers is regulated by its anionic nature and phase state

Influence of the bilayer composition on the binding and membrane disrupting effect of Polybia-MP1, an antimicrobial mastoparan peptide with leukemic T-lymphocyte cell selectivity

Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications

Antimicrobial peptide m2163 or m2386 identified from Lactobacillus casei ATCC 334 can trigger apoptosis in the human colorectal cancer cell line SW480

A parasporin from Bacillus thuringiensis native to Peninsular India induces apoptosis in cancer cells through intrinsic pathway

Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

Recent advances in anti-cancer protein/peptide delivery

Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: a comprehensive overview

Effect of the aspartic acid D2 on the affinity of Polybia-MP1 to anionic lipid vesicles

Synthesis and Solution Structure of the Antimicrobial Peptide Protegrin-1

Binding of tachyplesin I to DNA revealed by footprinting analysis: significant contribution of secondary structure to DNA binding and implication for biological action

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

Peptide antibiotics. The Lancet

The Central Hinge Link Truncation of the Antimicrobial Peptide Fowlicidin-3 Enhances Its Cell Selectivity without Antibacterial Activity Loss

Mechanism of action of antimicrobial peptide P5 truncations against Pseudomonas aeruginosa and Staphylococcus aureus

Antimicrobial activities of LL-37 and its truncated variants against Burkholderia thailandensis

Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug resistant bacteria

Effects of lysine-to-arginine substitution on antimicrobial activity of cationic stapled heptapeptides

The antimicrobial peptides and their potential clinical applications

The effect of acidic residues and amphipathicity on the lytic activities of mastoparan peptides studied by fluorescence and CD spectroscopy

Antimicrobial activity of doubly-stapled alanine/lysine-based peptides

Mono-substitution effects on antimicrobial activity of stapled heptapeptides

Antimicrobial and Hemolytic Activity of Stapled Heptapeptide Dimers

Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides

Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides

Effect of hydrophobic modifications in antimicrobial peptides

De novo design and their antimicrobial activity of stapled amphipathic helices of heptapeptides

Cysteine-stabilized αβ defensins: From a common fold to antibacterial activity

A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein

Antimicrobial activity of a halocidinderived peptide resistant to attacks by proteases

A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii

D-Cateslytin, a new antimicrobial peptide with therapeutic potential

Antimicrobial Peptides with High Proteolytic Resistance for Combating Gram-Negative Bacteria

Tryptic Stability of Synthetic Bactenecin Derivatives Is Determined by the Side Chain Length of Cationic Residues and the Peptide Conformation

Improving the Activity of Trp-Rich Antimicrobial Peptides by Arg/Lys Substitutions and Changing the Length of Cationic Residues

The Effect of Selective D-or N(alpha)-Methyl Arginine Substitution on the Activity of the Proline-Rich Antimicrobial Peptide, Chex1-Arg20

Sequence inversion and phenylalanine surrogates at the beta-turn enhance the antibiotic activity of gramicidin S

Bulky Nonproteinogenic Amino Acids Permit the Design of Very Small and Effective Cationic Antibacterial Peptides

Effect of N-terminal acetylation on lytic activity and lipid-packing perturbation induced in model membranes by a mastoparan-like peptide

N-Capping Effects of Stapled Heptapeptides on Antimicrobial and Hemolytic Activities

The role of Cterminal amidation in the membrane interactions of the anionic antimicrobial peptide, maximin H5

Three Novel Antimicrobial Peptides from the Venom of the Eusocial Bee Lasioglossum laticeps (Hymenoptera: Halictidae)

How C-Terminal Carboxyamidation Alters the Biological Activity of Peptides from the Venom of the Eumenine Solitary Wasp

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading

Antimicrobial activity and stability of stapled helices of polybia-MP1

Diaminodiacid-based solid-phase synthesis of peptide disulfide bond mimics

Bacteria Hunt Bacteria through an Intriguing Cyclic Peptide

An antimicrobial bicyclic peptide from chemical space against multidrug resistant Gram-negative bacteria

Cyclization of peptides with two chemical bridges affords large scaffold diversities

Arginine/Tryptophan-Rich Cyclic alpha/beta-Antimicrobial Peptides: The Roles of Hydrogen Bonding and Hydrophobic/Hydrophilic Solvent-Accessible Surface Areas upon Activity and Membrane Selectivity

Bridged bicyclic peptides as potential drug scaffolds: synthesis, structure, protein binding and stability

Systemic antibacterial activity of novel synthetic cyclic peptides

Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging

Enzymatic pathway for the bacterial degradation of the cyanobacterial cyclic peptide toxin microcystin LR

Antimicrobial activity of doubly-stapled alanine/lysine-based peptides

Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis

Exploring the links between peptoid antibacterial activity and toxicity

Peptoids successfully inhibit the growth of gram negative E. coli causing substantial membrane damage

Synthesis of Antimicrobial Peptoids

De Novo Design, Synthesis, and Characterization of Antimicrobial β-Peptides

Antimicrobial β-Peptides and α-Peptoids

Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections

Lysine-Based α-Peptide/β-Peptoid Peptidomimetics: Influence of Hydrophobicity, Fluorination, and Distribution of Cationic Charge on

Recent advances in protein and peptide drug delivery systems

Non-invasive delivery strategies for biologics

Current status and future potential of transdermal drug delivery

Skin permeabilization for transdermal drug delivery: recent advances and future prospects

Barrier properties of mucus

Is the oral route possible for peptide and protein drug delivery?

Oral delivery of peptides: opportunities and issues for translation

Microneedles for drug delivery via the gastrointestinal tract

A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules

Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance

Inhaled nanoparticles-a current review

Particle engineering techniques for inhaled biopharmaceuticals

Challenges and opportunities for the subcutaneous delivery of therapeutic proteins

Stimuli-responsive nanocarriers for drug delivery

Antimicrobial hydrogels: promising materials for medical application

Lipid-based nanocarriers for oral peptide delivery

PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing

Recent Developments in Antimicrobial-Peptide-Conjugated Gold Nanoparticles

A Peptide-Nanoparticle System with Improved Efficacy against Multidrug Resistant Bacteria

Multivalent gold nanoparticle-peptide conjugates for targeting intracellular bacterial infections

Preventive measures against transcutaneous device infections

Prosthetic-joint infections

Antimicrobial peptides in biomedical device manufacturing

Bacterial biofilms: a common cause of persistent infections

Tissue colonization in biomaterial-associated infection

Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Antimicrobial peptides: key components of the innate immune system

Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections

Antimicrobial peptides: old molecules with new ideas

Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin

Biomaterial-associated infection: locating the finish line in the race for the surface

Prevention of bacterial colonization on catheters by a one-step coating process involving an antibiofouling polymer in water

A lipid-and-polymerbased novel local drug delivery system-BonyPid™: From physicochemical aspects to therapy of bacterially infected bones

Esculentin-1a derived peptides kill Pseudomonas aeruginosa biofilm on soft contact lenses and retain antibacterial activity upon immobilization to the lens surface

Anti-adhesive antimicrobial peptide coating prevents catheter associated infection in a mouse urinary infection model

Efficiency of gold nanoparticles coated with the antimicrobial peptide indolicidin against biofilm formation and development of Candida spp

Antibacterial activity and cytocompatibility of an implant coating consisting of TiO2 nanotubes combined with a GL13K antimicrobial peptide

Titanium surfaces immobilized with the major antimicrobial fragment FK-16 of human cathelicidin LL-37 are potent against multiple antibiotic-resistant bacteria

Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145

Peptide-loaded microgels as antimicrobial and anti-inflammatory surface coatings

Antimicrobial Peptides in Cutaneous Wound Healing

Komodo dragon-inspired synthetic peptide DRGN-1 promotes wound-healing of a mixed-biofilm infected wound

Efficacy of the designer antimicrobial peptide SHAP1 in wound healing and wound infection

Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis

Collagen Synthesis Is Suppressed in Dermal Fibroblasts by the Human Antimicrobial Peptide LL-37

The Antimicrobial Peptides Psoriasin (S100A7) and Koebnerisin (S100A15) Suppress Extracellular Matrix Production and Proliferation of Human Fibroblasts

Identification of multiple peptides with antioxidant and antimicrobial activities from skin and its secretions of Hylarana taipehensis, Amolops lifanensis, and Amolops granulosus

Antimicrobial and antioxidant properties of the crude peptide extracts of Galatea paradoxa and Patella rustica

Protective effect of in ovo treatment with the chicken cathelicidin analog D-CATH-2 against avian pathogenic

The design of a cell-selective fowlicidin-1-derived peptide with both antimicrobial and anti-inflammatory activities

Highly Stabilized α-Helical Coiled Coils Kill Gram-Negative Bacteria by Multicomplementary Mechanisms under Acidic Condition

A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs

New approaches in peptide antibiotics

An Update on Fluoroquinolones: The Emergence of a Multisystem Toxicity Syndrome

Europe rules on harm from fluoroquinolone antibiotics

Combination Effects of Antimicrobial Peptides

The value of antimicrobial peptides in the age of resistance

Antimicrobial host defence peptides: functions and clinical potential

Antimicrobial resistance in livestock: antimicrobial peptides provide a new solution for a growing challenge

Antimicrobial Peptides as Potential Alternatives to Antibiotics in Food Animal Industry